[Expression, purification and antiviral activities of a new recombinant human interferon-lambda2].
OBJECTIVE
To express recombinant human interferon lambda2 in E.coli and to study its antiviral activities.


METHODS
According to preferred codons used in E.coli, the highly-expressed human interferon lambda2 gene was designed, synthesized and cloned into expression vector pBV220 and transfected into E.coli DH5alpha. The expressed product was purified by using CM FF and size exclusion chromatography. Its antiviral activities were tested on different cells.


RESULTS
The expressed product was calculated about 15% of the total E.coli protein. The purified protein reached about 90% purity. Its specific antiviral activity was about 1.5 x 10(6) IU/mg on WISH/VSV test system. It was shown that the antiviral activity of the product on primates-origin cells seemed to be much higher than that on other non-primates-origin cells, indicating that interferon lambda2 possessed more stringent species specificity as compared with interferon-alpha2b. New interferon lambda2 showed similar anti-HBV activity as interferon-alpha2b.


CONCLUSIONS
Recombinant human interferon lambda2 could be expressed on E.coli. The purified product showed more stringent species specificity and similar anti-HBV activity as compared with interferon-alpha2b.
Wang
Gang
G
State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute of Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 100052, China.
Li
Wu-ping
WP
Zhang
Cheng-hai
CH
Yi
Zuo-an
ZA
Zheng
Li-shu
LS
Zhang
Hui
H
Duan
Zhao-jun
ZJ
Hou
Yun-de
YD
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002522:Chlorocebus aethiops; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli / Q000235:genetics / Q000378:metabolism; D006515:Hepatitis B virus / Q000187:drug effects; D006801:Humans; D007378:Interleukins / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000302:isolation & purification / Q000494:pharmacology*; D014709:Vero Cells; D000095022:Interferon Lambda
D000998:Antiviral Agents; D007378:Interleukins; D011994:Recombinant Proteins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda